Scalable nanoprecipitation of niclosamide and<i>in vivo</i>demonstration of long-acting delivery after intramuscular injection

Hobson, James J.; Savage, Alison C.; Dwyer, Andrew; Unsworth, Catherine; Massam, J.; Arshad, Usman; Pertinez, Henry; Box, Helen; Tatham, Lee; Rajoli, Rajith K. R.; Neary, Megan; Sharp, Joanne; Valentijn, Anthony; David, Christopher; Curley, Paul; Liptrott, Neill J.; McDonald, Tom O.; Owen, Andrew; Rannard, Steve

doi:10.1039/d1nr00309g

Cited by 12 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nanohybrid was reported to have a particle size of less than 200 nm, with good colloidal stability and 60 % drug released after 24 h in pH 7.4 buffer. Furthermore, in serum circumstances, the nanohybrid demonstrated improved drug release behaviour, indicating that such a hybrid drug delivery system might be extremely useful in treating COVID-19 patients [44].…”

Section: Parenteral Delivery Of Niclosamide In Covid-19 Treatmentmentioning

confidence: 98%

“…Hence, several techniques such as co-crystals [35][36][37], solid lipid nanoparticles [35], dendrimers [38], micelles [8,39], nanosuspensions [40], nanoparticles [41], lipid emulsions [42], and nanocrystals [43] have been explored so far to improve niclosamide's water solubility and bioavailability in order to harness its potential in treating various cancers, metabolic disorders as well as bacterial and viral infections. The following section includes some of the most currently used approaches to improve the delivery of niclosamide for efficacious treatment of COVID-19 [44].…”

Section: Fig 1: Niclosamide's Antiviral Mode Of Action Against Sars-c...mentioning

confidence: 99%

See 1 more Smart Citation

Niclosamide: A Potential Treatment Option for Covid-19

et al. 2023

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global health hazard due to its rapid dissemination and limited treatment options. Identification of possible treatments that may kill the virus, speed up the recovery, or reduce the case fatality rate is a need of hour. However, developing and producing particular COVID-19 medicines and vaccines is a time-consuming process with possibilities of clinical failures due to safety or efficacy issue. Medication repositioning is a safer and quicker approach for dealing with the COVID-19 worldwide threat right now. Out of 48 FDA-approved medicines tested against SARS-CoV-2, niclosamide is one amongst few that has shown potential in vitro antiviral activity against SARS-CoV-2. However, the currently available oral conventional formulation of niclosamide results in systemic medication levels those are unsatisfactory to inhibit SARS-CoV-2. Hence, various formulation strategies have been adapted in order to achieve an optimum therapeutic outcome of niclosamide when delivered via oral, inhalation, and intranasal routes. Some of these formulations are presently undergoing clinical trials. The current review focuses on the mechanisms of action of niclosamide and its repurposing effectiveness against COVID-19. The delivery strategies to improve its bioavailability have been overviewed. The recently completed and ongoing clinical trials have also been summarized.

show abstract

Section: Parenteral Delivery Of Niclosamide In Covid-19 Treatmentmentioning

confidence: 98%

Section: Fig 1: Niclosamide's Antiviral Mode Of Action Against Sars-c...mentioning

confidence: 99%

Niclosamide: A Potential Treatment Option for Covid-19

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This means that nanosuspensions offer the highest drug loadings out of all nanomedicines. Nanosuspensions of a wide range of poorly water-soluble APIs can be produced via a number of routes, with milling, [129][130][131] nanoprecipitation, [132][133][134] high pressure homogenisation 135 and emulsion-templated freeze drying [136][137][138][139] being some of the most common methods.…”

Section: Nanosuspensionsmentioning

confidence: 99%

Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…160 Niclosamide-loaded albumin NPs, chitosan nanocarriers, biopolymer-derived nanocarriers, and lipid NPs demonstrated a highly viral entry inhibitory effect against SARS-CoV-2 in vitro and showed an extended circulating drug exposure in vivo, with a new, cheap, and scalable preparation process. 161 In sum, all these nanotherapeutic strategies can provide timely solutions for combating the pandemic and open the door for future explorations.…”

Section: Nanostructures For Postinfection Complicationsmentioning

confidence: 99%

Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives

Yayehrad¹,

Siraj²,

Birhanu³

et al. 2021

IJN

View full text Add to dashboard Cite

A serious viral infectious disease was introduced to the globe by the end of 2019 that was seen primarily from China, but spread worldwide in a few months to be a pandemic. Since then, accurate prevention, early detection, and effective treatment strategies are not yet outlined. There is no approved drug to counter its worldwide transmission. However, integration of nanostructured delivery systems with the current management strategies has promised a pronounced opportunity to tackle the pandemic. This review addressed the various promising nanotechnology-based approaches for the diagnosis, prevention, and treatment of the pandemic. The pharmaceutical, pharmacoeconomic, and regulatory aspects of these systems with currently achieved or predicted beneficial outcomes, challenges, and future perspectives are also highlighted.

show abstract

Scalable nanoprecipitation of niclosamide andin vivodemonstration of long-acting delivery after intramuscular injection

Abstract: The control of COVID-19 across the world requires the formation of a range of interventions including vaccines to elicit an immune response and immunomodulatory or antiviral therapeutics. Here, we demonstrate...

Cited by 12 publications

References 41 publications

Niclosamide: A Potential Treatment Option for Covid-19

Niclosamide: A Potential Treatment Option for Covid-19

Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions

Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives

Contact Info

Product

Resources

About